HILLEVAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.79 USD | +6.41% |
|
+3.98% | -20.31% |
| Apr. 05 | Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing | MT |
| Mar. 21 | Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 596.3 | 746.6 | 615.8 | - | - |
| Enterprise Value (EV) 1 | 596.3 | 468.3 | 615.8 | 615.8 | 615.8 |
| P/E ratio | -2.84 x | -5.28 x | -4.13 x | -3.65 x | -3.37 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 197 x |
| EV / Revenue | - | - | - | - | 197 x |
| EV / EBITDA | -9.16 x | -5.62 x | -3.79 x | -3.61 x | -3.22 x |
| EV / FCF | -9.03 x | -7.65 x | -3.79 x | -3.35 x | -2.92 x |
| FCF Yield | -11.1% | -13.1% | -26.4% | -29.8% | -34.3% |
| Price to Book | 1.7 x | 2.88 x | 2.93 x | 3.07 x | 3.53 x |
| Nbr of stocks (in thousands) | 35,644 | 46,516 | 48,149 | - | - |
| Reference price 2 | 16.73 | 16.05 | 12.79 | 12.79 | 12.79 |
| Announcement Date | 3/17/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 3.125 |
| EBITDA 1 | - | -65.11 | -132.9 | -162.3 | -170.7 | -191.3 |
| EBIT 1 | - | -65.11 | -133.3 | -165.9 | -212.5 | -255.2 |
| Operating Margin | - | - | - | - | - | -8,164.81% |
| Earnings before Tax (EBT) 1 | - | -159.8 | -123.6 | -158.4 | -204.9 | -248.5 |
| Net income 1 | -102.4 | -159.8 | -123.6 | -159.8 | -198 | -238.4 |
| Net margin | - | - | - | - | - | -7,627.84% |
| EPS 2 | -30.64 | -5.890 | -3.040 | -3.098 | -3.508 | -3.798 |
| Free Cash Flow 1 | - | -66 | -97.53 | -162.6 | -183.6 | -211 |
| FCF margin | - | - | - | - | - | -6,753.01% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 3/17/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | -11.31 | -12.81 | -17.89 | -23.1 | -28.96 | -30.08 | -33.57 | -39.41 | - | - | - | - | - |
| EBIT 1 | -11.31 | -12.81 | -17.89 | -23.1 | -28.96 | -30.18 | -33.91 | -40.29 | -42.6 | -45.33 | -39.7 | -33.79 | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -67.89 | -53.93 | -16.8 | -21.19 | -26.89 | -27.9 | -31.82 | -36.96 | -40.62 | -43.22 | -39.54 | -35.25 | - |
| Net income 1 | -67.89 | -53.93 | -16.8 | -21.19 | -26.89 | -27.9 | -31.82 | -36.96 | -40.62 | -43.22 | -39.54 | -35.25 | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -10.06 | -2.030 | -0.4500 | -0.5600 | -0.7100 | -0.7400 | -0.8100 | -0.7800 | -0.8480 | -0.9047 | -0.7389 | -0.6665 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 6/8/22 | 8/10/22 | 11/10/22 | 3/17/23 | 5/12/23 | 8/14/23 | 11/9/23 | 3/20/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | 278 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -66 | -97.5 | -163 | -184 | -211 |
| ROE (net income / shareholders' equity) | - | - | -46.4% | -63% | -70.7% | -76% |
| ROA (Net income/ Total Assets) | - | -71.9% | -37.4% | -47.2% | -51.7% | -55.8% |
| Assets 1 | - | 222.2 | 330.8 | 338.5 | 383 | 427.2 |
| Book Value Per Share 2 | - | 9.840 | 5.570 | 4.360 | 4.170 | 3.620 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | 10.7 | 6.5 | 6.5 | 6.5 |
| Capex / Sales | - | - | - | - | - | 208.1% |
| Announcement Date | 2/28/22 | 3/17/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.79
USD
Average target price
29
USD
Spread / Average Target
+126.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.31% | 616M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- HLVX Stock
- Financials HilleVax, Inc.
